- Home
- RBRK vs CRNX Comparison
RBRK vs CRNX Comparison
Compare RBRK & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBRK
- CRNX
- Stock Information
- Founded
- RBRK 2013
- CRNX 2008
- Country
- RBRK United States
- CRNX United States
- Employees
- RBRK N/A
- CRNX N/A
- Industry
- RBRK
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- RBRK
- CRNX Health Care
- Exchange
- RBRK NYSE
- CRNX Nasdaq
- Market Cap
- RBRK 5.8B
- CRNX 5.3B
- IPO Year
- RBRK 2024
- CRNX 2018
- Fundamental
- Price
- RBRK $43.10
- CRNX $54.72
- Analyst Decision
- RBRK Strong Buy
- CRNX Strong Buy
- Analyst Count
- RBRK 17
- CRNX 10
- Target Price
- RBRK $45.06
- CRNX $73.70
- AVG Volume (30 Days)
- RBRK 1.2M
- CRNX 655.3K
- Earning Date
- RBRK 12-05-2024
- CRNX 11-12-2024
- Dividend Yield
- RBRK N/A
- CRNX N/A
- EPS Growth
- RBRK N/A
- CRNX N/A
- EPS
- RBRK N/A
- CRNX N/A
- Revenue
- RBRK $732,883,000.00
- CRNX $1,038,999.00
- Revenue This Year
- RBRK $35.65
- CRNX N/A
- Revenue Next Year
- RBRK $28.21
- CRNX $494.25
- P/E Ratio
- RBRK N/A
- CRNX N/A
- Revenue Growth
- RBRK 24.70
- CRNX N/A
- 52 Week Low
- RBRK $28.34
- CRNX $28.50
- 52 Week High
- RBRK $45.90
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- RBRK N/A
- CRNX 41.37
- Support Level
- RBRK N/A
- CRNX $58.21
- Resistance Level
- RBRK N/A
- CRNX $62.53
- Average True Range (ATR)
- RBRK 0.00
- CRNX 2.48
- MACD
- RBRK 0.00
- CRNX -0.33
- Stochastic Oscillator
- RBRK 0.00
- CRNX 4.87
About RBRK RUBRIK INC
Rubrik Inc is a company that offers data security solutions to organizations ranging from the largest companies worldwide to mid-sized smaller customers. Its platform is architected to help organizations achieve cyber resilience, which encompasses cyber posture and cyber recovery. They enable organizations to confidently accelerate digital transformation and leverage the cloud to realize business agility.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.